Dapagliflozin in patients with heart failure and reduced ejection fraction
McMurray JJ, Solomon SD, Inzucchi SE
New England Journal of Medicine · 2019
This randomized controlled trial evaluates the intervention under study in relation to the primary clinical outcome. Includes 4,744 participants. Evidence level: Ia.
循证研究：达格列净治疗心衰研究
Key facts at a glance
- DOI
- 10.1056/NEJMoa1914103
- PMID
- 31492782
- Journal
- New England Journal of Medicine
- Year
- 2019
- Study type
- rct
- Evidence level
- Ia
- Sample size
- 4744
- Intervention
- Dapagliflozin 10mg/天 vs 安慰剂
- Primary outcome
- 心血管死亡或心衰恶化 (复合)
- Open access
- false
Study Overview
This randomized controlled trial enrolled 4,744 participants and examined the primary clinical outcome.
Key Findings
Results regarding the primary clinical outcome are presented.
Clinical Conclusions
See original publication for detailed findings. Evidence level: Ia.
Abstract
"This randomized controlled trial enrolled 4,744 participants, investigating the effects of Dapagliflozin 10mg/天 vs 安慰剂 on 心血管死亡或心衰恶化 (复合).
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed October 18, 2026. · Read our editorial policy